The CSL Limited (ASX: CSL) share price has edged lower since this time last month, down 2.38%.
While the global biotech didn’t release any market-sensitive news, investors appeared to be mixed about the company’s shares.
At market close on Wednesday, CSL shares finished trading at $264.50, up 0.82%.
What’s weighing down CSL shares?
A number of factors are playing against CSL shares for the moment as the COVID-19 pandemic begins to subside.
First and foremost, the S&P/ASX 200 Health Care Index (ASX: XHJ) has moved sideways since the start of 2022.
Investors appear to have focused their efforts on other performing sectors on the ASX such as the S&P/ASX 300 Metals & Mining Index (ASX: XMM). This consists of the top 300 ASX companies that are involved with gold, steel and precious metals.
And it is no surprise given the war in Ukraine, and inflationary movements that commodity prices have skyrocketed.
Market psychology can be a powerful force when crowd behaviour chases market rallies or sell-offs during downturns.
In addition, the company’s first half results provided an update on its plasma collection issues. It noted that plasma numbers were 18% higher than H1 FY21, but still slightly down on 2019 levels.
CSL opened 18 new facilities in the first half of FY22 to attract lapsed and new donors through its doors. For the remainder of the financial year, the company plans to open another 35 centres, expanding its presence, mostly across the United States.
Nonetheless, a number of brokers rated the company’s shares to pick up over the course of the year.
Morgan Stanley raised its outlook to “overweight” from “equal weight”, adding 7.9% to a 12-month price target of $302.
Based on the current CSL share price, this implies a potential upside of 14.2%.
Meanwhile, Citi cut its rating on CSL shares by 1.5% to $335. Based on Citi’s assessment, this implies an upside of almost 27% from where it trades today.
CSL share price summary
When looking from this time last year, the CSL share price has moved in circles registering a less than 15 gain.
Year to date has not fared well, losing 9% in value across the 4-month period.
CSL commands a market capitalisation of roughly $127.41 billion, making it the third largest company on the ASX.
The post Why has the CSL share price struggled in the past month? appeared first on The Motley Fool Australia.
Should you invest $1,000 in CSL right now?
Before you consider CSL, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and CSL wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of January 13th 2022
More reading
- Should ASX investors buy the dip in the CSL share price?
- 2 blue chip ASX 200 shares analysts rate as buys this month
- Top brokers name 3 ASX shares to buy today
- ASX 200 healthcare shares were chronically ill last quarter. Take a look
- How is the CSL share price performing against its sector in 2022?
Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/nO4t5PB
Leave a Reply